Aurobindo Pharma’s JV receives SEC recommendation for pneumococcal 15 valent vaccine

27 Dec 2022 Evaluate

Aurobindo Pharma’s Joint Venture (JV) company-- Tergene Biotech has received Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) recommendation to manufacture and market 15-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV15) with three dose schedule (3 +0) for administration into the pediatric age group of 6, 10 and 14 weeks.

PCV15 vaccine was developed by Tergene Biotech and manufactured at AuroVaccines, which is a wholly owned subsidiary of Aurobindo Pharma with capabilities in vaccines development and manufacturing. Aurobindo Pharma holds 80% stake in the Joint Venture company, Tergene Biotech.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1148.35 -10.15 (-0.88%)
16-May-2024 13:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1509.50
Dr. Reddys Lab 5767.40
Cipla 1407.70
Zydus Lifesciences 999.85
Lupin 1674.45
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.